Market Context — Why This Technology, Why Now

The biotech industry faces increasing pressure for higher reproducibility and efficiency in cell culture, critical for scaling up regenerative therapies, accelerating drug discovery, and commercializing cultivated meat. Regulatory bodies and investors demand robust, predictable outcomes. This technology directly supports these trends by providing a stable, controlled culture environment, reducing experimental variability, and enabling faster, more cost-effective development of advanced biological products.

Key Competitive Advantages
01

Stabilizes Gene Expression: Suppresses cell proliferation variability caused by unknown growth factors, stabilizing gene expression and maximizing research reproducibility.

02

Enhances Reproducibility and Quality: Eliminates external factor influence on culture environment, significantly reducing experimental variability and contributing to uniform cell culture product quality.

03

Simplifies Manufacturing Process: Simplifies hydrogel manufacturing through hydrophilic polymer radiation cross-linking, leading to reduced production costs.

Market Opportunity
Regenerative Medicine
$300M–$400M globally (AI est.)
Enhancing reproducibility in stem cell differentiation and proliferation is crucial for tissue and organ regeneration. This technology accelerates the development of high-quality regenerative medicine products.
Advanced therapy medicinal product developers Stem cell research institutes Biotech firms specializing in tissue engineering
Drug Discovery Screening
$500M–$600M globally (AI est.)
Stabilizing the culture environment directly improves screening accuracy for 3D cell cultures and organoid-based disease models, boosting new drug development efficiency.
Pharmaceutical R&D divisions Contract research organizations (CROs) Organoid and 3D cell culture platform providers
Cultivated Meat Production
$10B–$15B globally (AI est.)
Commercial cultivated meat production requires large-scale, uniform cell cultures. This technology provides a stable scaffold, contributing to reduced production costs and consistent quality, accelerating commercialization.
Cultivated meat startups and scale-ups Food technology companies Bioreactor and cell culture media manufacturers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

The patent was granted after successfully overcoming examiner rejections with precise arguments and amendments, indicating a robust and valid scope of rights with low invalidation risk. It is broadly protected by 31 claims, reflecting a strong technical foundation and meticulous patenting strategy.

Competitive White Space

This patent primarily protects the hydrogel's composition and its impact on cell proliferation and gene expression stability. Licensees could develop additional IP in areas such as advanced bioreactor systems, automated cell harvesting, or integrated AI-driven culture monitoring platforms.

Economic Impact
~$150K/year estimated R&D cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming 5 researchers conduct cell culture experiments 200 days/year, with 10% requiring re-experiments due to reproducibility issues. At ~$350/re-experiment (AI est.) for reagents and personnel, total annual re-experiment cost is ~$350K (AI est.). This technology could reduce that by 50%, saving ~$150K/year (AI est.).

Speed to Market
3× faster than in-house development
This technology's specific requirements, such as defined cell proliferation activity and elasticity in a radiation cross-linked hydrogel, are clearly outlined in the patent claims. This allows licensees to significantly shorten the basic research phase and immediately begin application development. As a research outcome from a national R&D agency, the technology boasts high reliability, reducing validation costs for implementation and enabling early market entry.
Competitive Positioning

X: Cell Culture Reproducibility & Stability
Y: R&D Efficiency

Business Models & Applications
📝 Technology Licensing
Provide manufacturing know-how and usage rights, enabling licensees to integrate this technology into their product development and research. Facilitates rapid market entry and competitive advantage.
🤝 Joint Development (Applied Research)
Collaborate on optimizing hydrogel composition for specific cell types or applications, aiming for tailored solutions and accelerated market introduction.
📦 Contract Manufacturing (Hydrogel Supply)
Manufacture and supply the hydrogel itself to licensees, ensuring a stable supply of high-quality cell culture scaffold materials.
Adjacent Application Opportunities
🔬 Drug Discovery & Research
High-Precision 3D Cell Culture Platform
This technology's hydrogel could form the foundation for 3D cell culture platforms that more closely mimic in-vivo environments. This has the potential to significantly enhance the accuracy of drug screening and disease model research, potentially increasing new drug development success rates by over 20%.
🥩 Food & Biotech
High-Efficiency Scaffold for Cultivated Meat Production
Applied as a scaffold material for cultivated meat, this technology promotes efficient cell proliferation and tissue formation. Its stable culture environment and superior biocompatibility could reduce production costs by 15-20% and stabilize product quality, accelerating the commercialization of cultivated meat.
🏥 Medical Devices
Implantable Tissue Regeneration Devices
Utilizing this biocompatible hydrogel as a scaffold for implantable tissue regeneration devices could precisely control the proliferation and differentiation of specific cells. This is expected to accelerate the repair and regeneration of damaged tissues or organs, potentially reducing recovery times by 25%.
Integration Roadmap — Estimated 18-Month Deployment
Phase 1: Technology Evaluation & Validation
Duration: 3 months
Evaluate the suitability of this hydrogel material for the licensee's existing cell culture protocols and target cell types, conducting initial validation.
Phase 2: Prototype Development & Optimization
Duration: 6 months
Based on initial validation, optimize the hydrogel composition and shape for the licensee's specific application and develop a prototype.
Phase 3: Commercialization & Mass Production Preparation
Duration: 9 months
Conduct final evaluation of the optimized hydrogel for commercialization, advancing scale-up of manufacturing processes and establishing quality control systems.
Technical Feasibility
This technology specifies a clear manufacturing method using hydrophilic polymer radiation cross-linking and strict numerical ranges for cell proliferation activity and elasticity. This facilitates standardizing hydrogel material preparation protocols for integration into existing cell culture environments, allowing for material replacement validation without significant new equipment investment. The clear technical specifications reduce uncertainty during adoption.
Success Scenario
Implementing this technology could dramatically improve the reproducibility of previously unstable cell cultures, potentially shortening R&D timelines by up to 30%. This could accelerate the development of new drugs and regenerative medicine products, reducing time to market. Furthermore, uniform culture product quality could enhance the reliability of final products.
Patent Record
APPLICATION NO.
特願2023-166391
REGISTRATION NO.
7658611
FILING DATE
2023/09/27
GRANT DATE
2025/03/31
EXPIRATION DATE
2043/09/27
PATENT HOLDER
国立研究開発法人量子科学技術研究開発機構
Examination History
2023年10月10日
手続補正書（自発・内容）
2023年10月24日
手続補正書（自発・内容）
2023年10月24日
出願審査請求書
2024年10月29日
拒絶理由通知書
2024年12月16日
意見書
2024年12月16日
手続補正書（自発・内容）
2025年03月11日
特許査定